BillionToOne is trading at $94.50, up +4.22%, driven by the Northstar Origin launch.
- Launched September 1, 2026, Northstar Origin is a liquid-biopsy add-on predicting tissue of origin from a single blood draw.
- Northstar Select expanded from 84 to 102 genes; the launch reported 87% top-prediction and 91% top-three accuracy in a 1,578-patient validation cohort.
- Broader biotech weakness and risk-off markets remain offsetting pressures.